Why is Aurobindo Pharma falling/rising?

As of 18-Jul, Aurobindo Pharma Ltd. is experiencing a decline in its stock price, currently at 1,141.00, which reflects a decrease of 12.5 or 1.08%. The stock has underperformed its sector by 0.53% today, and while it is higher than its 5-day and 20-day moving averages, it remains lower than the 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has shown a return of 1.47%, outperforming the Sensex, which declined by 0.90%. However, the stock has faced a significant drop of 14.69% over the past year, despite a 5.3% increase in profits, indicating a disconnect between stock performance and earnings growth. The falling investor participation, with a 23.54% decrease in delivery volume compared to the 5-day average, may also contribute to the stock's downward pressure.
In the broader market context, Aurobindo Pharma's recent performance contrasts with the Sensex, which has gained 4.63% year-to-date, while Aurobindo has declined by 14.54%. Despite the stock's attractive valuation, indicated by a low debt-to-equity ratio and a price-to-book value of 2, the overall market sentiment appears to be affecting its performance negatively. The high institutional holdings at 41.31% suggest that informed investors are backing the company, yet the stock's recent underperformance relative to both its sector and the broader market may reflect concerns about its growth prospects, as evidenced by the high PEG ratio of 3.7.